loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
Open ICICI 3-in-1 Account

Epigral Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Epigral Ltd. 04 May 2026 13:08 PM
Result PDF

Q4FY26 & FY26 Result Announced for Epigral Ltd.

Specialty Chemicals company Epigral announced Q4FY26 & FY26 results

Standalone Financial Highlights

  • Revenue from operations for Q4FY26 was Rs 736.16 crore, an increase of 17.29% YoY compared to Rs 627.63 crore in Q4FY25 and a growth of 23.28% QoQ against Rs 597.12 crore in Q3FY26.
  • Total income for Q4FY26 stood at Rs 735.59 crore, up 16.57% YoY from Rs 631.03 crore and up 22.05% QoQ from Rs 602.68 crore.
  • Net Profit after tax for Q4FY26 was Rs 81.93 crore, reflecting a decrease of 5.41% YoY from Rs 86.62 crore but a substantial growth of 109.27% QoQ from Rs 39.15 crore.
  • For FY26, Standalone Revenue from operations was Rs 2,527.18 crore, showing a marginal decline of 0.90% compared to Rs 2,550.13 crore in FY25.
  • Annual Net Profit after tax for FY26 reached Rs 333.01 crore, down 6.64% from Rs 356.70 crore in the previous financial year.
  • Earnings per share (not annualized) for Q4FY26 was Rs 18.99, while the annual EPS for FY26 stood at Rs 77.19.

Consolidated Financial Highlights

  • Consolidated Revenue from operations for Q4FY26 reached Rs 736.16 crore, marking a 17.29% YoY increase from Rs 627.63 crore and a 23.28% QoQ increase from Rs 597.12 crore.
  • Total consolidated income for the quarter was reported at Rs 735.59 crore, up 16.57% YoY and 22.05% QoQ.
  • Consolidated Net Profit after tax for Q4FY26 was Rs 80.95 crore, representing a 6.84% YoY decline from Rs 86.89 crore but an increase of 107.01% QoQ compared to Rs 39.11 crore.
  • For the full year FY26, Consolidated Revenue from operations stood at Rs 2,527.18 crore, compared to Rs 2,550.13 crore in FY25, a decrease of 0.90%.
  • Annual Consolidated Net Profit after tax for FY26 was Rs 331.97 crore, a 7.19% decrease from Rs 357.69 crore in FY25.
  • Consolidated annual earnings per share for FY26 was Rs 76.95.

Business Highlights

  • Segment Performance: The company’s business activities fall within a single business segment, namely "Chloro Alkali & its Derivatives," which accounts for its entire operational performance.
  • Dividend: The Board of Directors recommended a final dividend of Rs 5.00 (50%) per Equity Share of face value of Rs 10 each for FY26.
  • Taxation: Effective from FY26, the company exercised the option permitted under Section 115BAA of the Income-tax Act, 1961. This resulted in the recognition of a one-time deferred tax credit of Rs 80.87 crore in the Statement of Profit and Loss.
  • Investment in Renewable Energy: During FY26, the company entered into a Share Subscription and Shareholders' Agreement to invest Rs 0.13 crore for a 26% equity stake and Rs 21.25 crore in Optionally Convertible Debentures of Pro-Zeal Green Power Ten Private Limited. The investment supports a 19.80 MW Wind Solar Hybrid Power plant in Gujarat.
  • Labour Codes: The company assessed the incremental liability for gratuity and leave encashment regarding the new Labour Codes notified on November 21, 2025, and concluded the impact is not material to the financial results.

Maulik Patel, Chairman & Managing Director, Epigral, said: “In Q4FY26, we delivered record revenue of Rs 736 crore, driven by a 15% sequential increase and 14% YoY growth in volumes. This performance reflects strong demand conditions and a full recovery post-scheduled maintenance in Q3. Improved utilization levels and stabilization in raw material costs supported EBITDA margins of 23%.

While FY26 saw some impact due to an extended monsoon and planned maintenance in the first half, demand recovery began in November and strengthened through Q4. We expect this momentum to continue into FY27, subject to global macro conditions”.

“Our diversified product portfolio continues to provide resilience amid geopolitical uncertainties, including developments in West Asia. At the same time, our ongoing capex projects for Epichlorohydrin and CPVC expansion are progressing as planned and within budget. Once commissioned, these plants will address India’s growing demand and enhance our financial performance.

With these projects nearing completion and a pipeline of new initiatives focused on further integration, we are well-positioned to deliver consistent growth and long-term value for our stakeholders.”

Result PDF

Result PDF

Specialty Chemicals company Epigral announced Q3FY26 results

  • Plant utilization stood at 78% similar to previous quarter.
  • The company posted a revenue of Rs 603 crore for Q3FY26 as against Rs 649 crore recorded in Q3YF25.
  • EBITDA margin stood at 17% vs 23% in Q2FY26 on account of drop in realizations and increase in cost of raw materials.
  • PAT stood at Rs 39 crore compared to Rs 104 crore in Q3FY25.

Maulik Patel, Chairman & Managing Director, Epigral said: “This quarter delivered marginal sequential topline growth. While demand softened before mid-November due to extended monsoon conditions, the market has strengthened notably since then, and we anticipate sustained positive momentum ahead.

Margins in Q3FY26 reflected temporary pressures from softer realizations on select products, elevated raw material costs, and inventory dynamics. With the improving market scenario, we anticipate positive outcomes starting Q4FY26.

Our capacity expansion projects for CPVC, Epichlorohydrin, and Wind Solar Hybrid Power Plant are progressing smoothly on schedule, set for timely commissioning. These initiatives will drive growth from FY27 onwards. We're also advancing new projects and look forward to sharing updates soon.

We remain committed to our journey of scalable, profitable growth optimizing capital allocation, enhancing integration, and delivering lasting value for all stakeholders.”

Result PDF

Specialty Chemicals company Epigral announced Q2FY26 results

Q2FY26 Financial Highlights:

  • Plant utilization stood at 78% vs 73% in previous quarter
  • Sales volume grew by 2% compared to previous quarter
  • QoQ Revenue dropped by 4% to Rs 589 crore on account of drop in realizations in few of the products
  • EBITDA margin stood at 23% vs 27% in Q1FY26 on account of drop in realizations and lower utilization
  • PAT stood at Rs 51 crore

H1FY26 Financial Highlights:

  • Plant utilization stood at 75% vs 83% in H1FY25
  • Sales volume dropped in H1FY26 majorly on account of off season for few of the products and we expect sales volume to improve in H2FY26
  • Revenue dropped by 6% to Rs 1,204 crore on account of drop in sales volume
  • EBITDA margin stood at 25% vs 28% in H1FY25 on account of drop in realizations and lower utilization
  • Net Debt stood at Rs 496 crore vs Rs 489 crore as on 31st March 2025
  • ROCE stood at 21% and Net Debt/EBITDA stood at 0.8x

Maulik Patel; Chairman and Managing Director – Epigral said: “This quarter ended with lower revenue on account of low sales volume and drop in realization of few products. Volume drop was majorly on account of extended monsoon which is off season for few products.

Overall plant utilization stood at 75% for H1FY26 and we expect utilization to improve in H2FY26, as extended monsoon is over and maintenance work at plant is also completed, resulting in better H2 compared to H1.

Our project to expand capacity of CPVC, Epichlorohydrin and Wind Solar Hybrid power plants are moving as per schedule and expected to be commissioned within committed timelines. These projects will drive growth from FY2027 onwards. We have further moved a step closer for the new projects. We will be announcing the same once it is freezed and approved by the board.

We will continue to advance along our path of scalable profitable growth, optimize capital allocation, strengthen our integration, and create enduring value for all stakeholders.”

Result PDF

Specialty Chemicals company Epigral announced Q1FY26 results

  • YoY Revenue dropped by 6% to Rs 615 crore. Revenue contribution from Derivatives & Specialty business stood at 50%.
  • EBITDA dropped by 7% to Rs 163 crore, however EBITDA margin remained unchanged at 27% on account of sustained focus on efficiency and product mix.
  • PAT stood at Rs 160 crore, however PAT excluding deferred tax liability benefit stood at Rs 79 crore as against Rs 86 crore in Q1FY25.
  • Plant utilization stood at 73%.
  • ROCE grew to 24% as on 30th June 2025 vs 21% as on 30th June 2024 due to improved earnings.
  • Net Debt/EBITDA reduced to 0.6x as on 30th June 2025 vs 1.6x as on 30th June 2024 on account of improvement in EBITDA and reduction in Net Debt.

Maulik Patel; Chairman & Managing Director, Epigral said: “Q1FY26 quarter ended with slightly lower volume and drop in realizations, however we maintained our EBITDA margin of 27% on account of sustaining efficiency level and better product mix. We expect H2FY26 to be stronger compared to H1FY26.

Revenue contribution from Derivatives and Specialty business stood at 50% and we expect this to further increase. Our capex projects of expanding CPVC and Epichlorohydrin capacity are moving as per schedule and are expected to be commissioned within the target timeline and budget. We are still left with a land parcel in the current complex for which we will announce a capex to further strengthen our integrated complex.

We are working on the new chemistry at our new land parcel. This new chemistry project will be on similar lines of our earlier projects, i.e. import substitution products where demand is expected to grow in double digits and where we can generate good ROCE.

We continue our journey to move forward in our direction of scalability with profitability, strengthening our integration and creating value for our stakeholders.”

Result PDF

Specialty Chemicals company Epigral announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • YoY Revenue grew by 20% to Rs 631 crore, on account of volume growth from Derivative products.
  • Revenue contribution from Derivatives & Specialty business increased to 52% in Q4FY25 vs 48% in Q4FY24.
  • EBITDA grew by 12% to Rs 173 crore vs Rs 155 crore in Q4FY24, and EBITDA margin stood at 28%.
  • PAT rose by 13% to Rs 87 crore.
  • ROCE grew to 25% as on 31st March 2025 vs 18% as on 31st March 2024 due to improvement in earnings.
  • Net Debt/EBITDA significantly reduced to 0.7x as on 31st March 2025 vs 2.0x as on 31st March 2024 on account of improvement in EBITDA and reduction in net debt.

FY25 Financial Highlights:

  • Highest ever revenue of Rs 2,565 crore, growth of 33% on account of volume growth from Derivative products.
  • Revenue contribution from Derivatives & Specialty business increased to 54% in FY25 vs 45% in FY24.
  • EBITDA grew by 48% to Rs 711 crore vs Rs 481 crore in FY24.
  • EBITDA margin stood at 28% in FY25 vs 25% in FY24 on account of a better product mix, led by contribution from new projects.
  • PAT jumped by 82% to Rs 357 crore.

Maulik Patel, Chairman and Managing Director, Epigral, said: “We ended FY25 with the highest ever revenue of Rs 2,565 crore, a growth of 33% compared to the previous year. This growth is on account of a volume rise of 11%, majorly from high-value products. Derivatives & Specialty business volume grew by around 24% in FY25, and its contribution to revenue touched 54% compared to 45% in FY24.

Considering the growth opportunity, we further announced expanding our CPVC and Epichlorohydrin capacity, which are expected to be commissioned in the first half of FY27 and will contribute from FY27 onwards. Once these projects reach optimum utilisation, our integrated complex will further strengthen.

We are geared up and strengthened our position, to grow further, by focusing on import substitute products, further diversifying and increasing Derivatives & Specialty business and with prudence allocation of capital, rewarding our stakeholders.”

Result PDF

Specialty Chemicals company Epigral announced Q3FY25 results

Q3FY25 Financial Highlights:

  • Revenue stood at Rs 649 crore, growth of 37% YoY on account volume growth from Derivative products.
  • Revenue contribution from Derivatives & Specialty business increased to 50% in Q3FY25 vs 47% in Q3FY24.
  • EBITDA grew by 49% to Rs 183 crore vs Rs 123 crore in Q3FY24.
  • EBIDTA margin stood at 28% vs 26% in Q3FY24. o PAT jumped by 110% to Rs 104 crore. PAT margin grew to 16% vs 10% in Q3FY24.
  • ROCE grew to 25% as on 31st December 2024 vs 18% as on 31st December 2023.
  • Net Debt / EBITDA significantly reduced to 0.8x as on 31st December 2024 vs 1.96x as on 31st December 2023 on account of improvement TTM EBITDA and reduction in Net Debt.

Maulik Patel, Chairman and Managing Director, Epigral said: “Epigral’s revenue grew by 37% in Nine months of FY25 on account 15% growth in sales volume from Derivatives business and high value products. The diversification strategy of our company has played a key role in witnessing consistent and stable growth in this subdued demand scenario. Revenue contribution from Derivatives business stood at 54% for 9MFY25 vs 44% in 9MFY24”

“Epigral is a growth-focused company and the volume in FY25 grew on account of various projects commissioned in the recent past. These projects will further contribute in FY26 along with a contribution from Chlorotoluenes Value Chain, it is expected to get commissioned in the current quarter. Further we are expanding and doubling our CPVC Resin and Epichlorohydrin capacity and we expect volume contribution from these projects from FY27 onwards.

At Epigral we are moving in line with our strategy to grow consistently along with strengthening our integrated complex and catering to diversified industries for creating value for our stakeholders.”

Result PDF

Specialty Chemicals company Epigral announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Revenue stood at Rs 632 crore, growth of 32% YoY on account of volume growth from Derivative products.
  • Revenue contribution from Derivatives & Specialty business increased to 59% in Q2FY25 vs 46% in Q2FY24.
  • EBITDA stood at Rs 178 crore vs Rs 108 crore in Q2FY24, grew by 65% YoY.
  • EBIDTA margin stood at 29% in Q2FY25 vs 23% in Q2FY24 on account of increase in utilization and volume contribution from new projects commissioned.
  • PAT grew by 111% to Rs 81 crore. PAT margin grew to 13% vs 8% in Q2FY24.
  • ROCE grew to 24% as on 30th September 2024 vs 21% as on Q2FY24.
  • Net Debt / EBITDA reduced to 1.4x as on 30th September 2024 vs 1.8x as on Q2FY24.

Q2FY25 Operational Highlights:

  • Sales volume grew 6% YoY, it majorly comes from Derivatives and Specialty business.
  • Capacity utilization stood at 83% in Q2FY25 vs 77% in Q2FY24.
  • YoY realizations dropped for all the products in range of 1% to 7%, except for Chloromethanes.
  • Caustic Soda realization dropped by 9% QoQ. Realization marginally improved for value added products.

H1FY25 Financial Highlights:

  • Revenue stood at Rs 1,285 crore, growth of 37% on account of volume growth from Derivative products.
  • Revenue contribution from Derivatives & Specialty business increased to 56% in H1FY25 vs 42% in H1FY24.
  • EBITDA stood at Rs 355 crore vs Rs 203 crore in H1FY24, grew by 75%.
  • EBIDTA margin stood at 28% in H1FY25 vs 22% in H1FY24 on account of increase in utilization and volume contribution from new projects commissioned.
  • PAT grew by 139% to Rs 166 crore. PAT margin grew to 13% vs 7% in H1FY24

H1FY25 Operational Highlights:

  • Sales volume grew 17% YoY, it majorly comes from Derivatives and Specialty business.
  • Capacity utilization stood at 83% in H1FY25 vs 74% in H1FY24.
  • Realizations dropped for all the products in H1FY25 vs H1FY24

Maulik Patel; Chairman and Managing Director, Epigral said: “Epigral witnessed the topline growth of 37% in H1FY25, on account of 17% sales volume growth coming from high value products of Derivatives and Specialty business, despite marginal drop in realizations for all the products. Revenue contribution from Derivative and Specialty business has reached to 59% in Q2FY25 vs 46% in Q2FY24”.

“At Epigral we are focused on continuous growth and entering products which are 1st time in India. In line with that, we had entered into CPVC and ECH, import substitute products. Considering the acceptance of our product, market size and growing demand for both the products, we are excited to further expand in both the products and double it from our existing capacity. The additional capacities are expected to get commissioned by H1Y27 and these projects are expected to contribute FY27 onwards. Our strategy to diversify into value added products, strengthening our integrated complex and sustained investment in capex will help us efficiency of scale and create value for our shareholders,”

Result PDF

Speciality Chemicals company Epigral announced Q1FY25 results:

Financial Highlights:

  • Highest ever quarterly revenue of Rs 651 crore, growth of 43% YoY and 24% QoQ on account of volume growth
  • Revenue contribution from Derivatives & Specialty segment increased to 53% in Q1FY25 vs 37% in Q1FY24
  • EBITDA stood at Rs 176 crore vs Rs 95 crore in Q1FY24. Growth of 85% YoY and 14% QoQ
  • EBIDTA margin stood at 27% in Q1FY25 vs 21% in Q1FY24 on account of increase in utilization and volume contribution from new projects commissioned
  • PAT stood at Rs 86 crore. PAT margin stood at 13% vs 7% in Q1FY24
  • ROCE stood at 21% as on 30th June 2024 vs 17% as on 31st March 2024
  • Net Debt / EBITDA stood at 1.59x as on 30th June 2024 vs 1.99x as on 31st March 2024

Operational Highlights:

  • Volume grew 29% YoY and 14% QoQ. Major growth comes from Derivatives & Specialty business
  • Capacity utilization stood at 83% in Q1FY25 vs 71% in Q1FY24
  • QoQ realizations dropped for all the products in range of 1% to 7%, except for Caustic Soda

Commenting on the results Maulik Patel; Chairman and Managing Director – Epigral said: “Epigral witnessed highest ever quarterly revenue of Rs. 651 crore in the quarter under review. The company delivered volume growth of 29% YoY and 14% QoQ; this growth is primarily attributed to efficient utilization of capacities and also volume from new projects commissioned. Revenue contribution from Derivatives & Specialty business rose sharply and stood at 53% in Q1FY25 vs 37% in Q1FY24”.

“In the April to June 2024 quarter, we commissioned CPVC Resin and Compound facility and by the end of current quarter we expect to commission Chlorotoluenes Value Chain facility, both these projects will drive growth for Epigral in FY2025 and FY2026. We are moving in line with our long term vision to become fully integrated complex catering to diversified industries and grow consistently to create value for our stakeholders.”

Result PDF

Specialty chemicals company Meghmani Finechem announced Q1FY24 results:

  • Revenue from operations of Rs 455 crore in Q1FY24 compared to Rs 533 crore in Q1FY23, down 15% YoY
  • EBITDA of Rs 95 crore in Q1FY24 compared to Rs 187 crore in Q1FY23, down 49% YoY
  • PAT of Rs 32 crore in Q1FY24 compared to Rs 108 crore in Q1FY23, down 71% YoY

Commenting on the results Maulik Patel, Chairman and Managing Director, MFL said, “FY24 started with a quarter that witnessed global level slowdown and inventory destocking, impacting the chemical industry both at demand level and also at realization level. MFL too got impacted during the quarter gone by, on account of the drop in realizations. However, MFL achieved volume growth of 11% YoY in Q1FY24; this volume growth is in line with our expansion plans resulting in volume coming from CPVC Resin, Epichlorohydrin, and Hydrogen Peroxide. Revenue contribution from Derivatives and Specialty Chemical stood at 38% compared to 21% for a similar period last year. We estimate this volume growth story will continue further as these new projects will further contribute in FY24.

Considering our long-term vision, we are on schedule for our expansions of CPVC Resin of 45,000 TPA and Chlorotoluene value chain, this will drive volume growth in FY25. Our R&D centre is almost ready; hence we are ready with another strong pillar for our future growth in the Specialty Chemical segment.

We believe that the current scenario is a phase that will pass and the long-term story remains intact. Hence, we are preparing ourselves for long-term growth and we are moving in that direction.

Our board has taken the initiative to rename our company Epigral. This activity is proposed to strengthen our corporate brand in line with our commitment to transform the company as a global multi-product chemical conglomerate and enhance our reputation as an integral partner for esteemed clients and our stakeholders.”

 

 

Result PDF

Specialty Chemicals Company Meghmani Finechem announced FY23 & Q4FY23 results:

  • FY23:
    • Revenue from operations rose 41% to Rs 2,188 crore as against Rs 1,551 crore in FY22 on account of higher realization compared to last year and volume growth from existing products as well as new products
    • Revenue contribution from derivatives & specialty chemical segment increased to 30% in FY23 vs 25% in FY22
    • EBITDA grew 35% to Rs 689 crore. Margin stood at 31% in FY23 vs 33% in FY22 on account of the high cost of inventory compared to realization
    • PAT grew 40% to Rs 353 crore as against Rs 253 crore in FY22 and PAT margin stood at 16% (16% in FY22)
    • Net debt/EBITDA stood at 1.3x (1.9x in FY22). Net debt/equity stood at 0.8x (1.3x in FY22)
    • Total debt decreased by Rs 112 crore to Rs 877 crore (Rs 989 crore in FY22)
  • Q4FY23:
    • Volume growth of 15% YoY (13% QoQ) – Led by new product CPVC resin and epichlorohydrin contributed and growth in the volume of caustic soda and hydrogen peroxide
    • Capacity utilization of hydrogen peroxide reached 98% and CMS reached 102%
    • Realization - caustic soda dropped by 23%, chloromethanes dropped by 13% and hydrogen peroxide increased by 1%
    • Revenue grew 13% to Rs 562 crore as compared to Rs 499 crore in Q4FY22 on account of volume growth of 15%
    • Revenue contribution from derivatives & specialty chemical segment increased to 38% in Q4FY23 vs 19% in Q4FY22
    • PAT stood at Rs 77 crore in Q4FY23 as against Rs 99 crore in Q4FY22

Commenting on the results Maulik Patel, Chairman and Managing Director – MFL, said: “FY 2022-23 was a very exciting year, despite business undergoing through lot of volatility. Realizations were at their peak at the start of the year and dropped sharply by the end of the year. Our strategy to diversify in high-value new products and continuous expansion has brought us volume growth of 15% YoY and 13% QoQ. Revenue contribution from Derivatives & Specialty Chemical segment touched 38% of our revenue in Q4FY23 and our efforts are to further enhance revenue share from this segment. All our future expansion plans are towards this segment.”

“Our new expansions that got commissioned in FY23, contributed marginally in FY23, however in the current fiscal (FY24) a sizeable volume growth is expected from these commissioned plants. Further expansions that we are currently working in FY24 will drive growth for FY25 With our focus on continuous expansion and strengthening our integrated complex, we are geared to bring consistent growth to business,” he added.

 

 

Result PDF

Trending News

L&T Wins Major Residential, Luxury Projects in Mumbai, Hyderabad, Karnataka (₹2.5K-5K Cr)

L&T has announced that its Buildings & Factories (B&F) vertical has secured multiple “Large” real-estate orders across Hyderabad, Mumbai and Karnataka. 

Published on 08-May-2026 09:14

Bharat Forge Q4: Revenue rises 4.5% to ₹2,261 cr, loss at ₹118 cr on subsidiary provision

Standalone revenues for the quarter came in at ₹ 2,261 crore (up 4.5% YoY), amidst an ~8% de-growth in tonnage at 62,201 tonnes

Published on 08-May-2026 09:13

Lupin Q4 Revenue Jumps 33% to ₹7,392Cr, EBITDA Soars 68% on Strong US, Emerging Market Growth

Revenues for the quarter grew by ~33% YoY to ₹7,392 crore, primarily driven by the US

Published on 08-May-2026 09:12

Udupi-CSL Secures ₹100-250 Cr Order from Adani’s Ocean Sparkle for 4 High-Capacity ASD Tugs

Udupi Cochin Shipyard Limited (Udupi-CSL), a wholly owned subsidiary of Cochin Shipyard Ltd (CSL)

Published on 08-May-2026 09:11

Wonderla Q4 Revenue Soars 40% to ₹136Cr, Driven by New Chennai Park and Stronger Visitor Footfalls.

Wonderla Ltd. reported strong set of results driven by robust performance in the newly inaugurated Chennai Park. Revenues witnessed 40.4% YoY growth to Rs.135.8cr in Q4FY28. 

Published on 08-May-2026 09:10

RECPDCL Tenders Major Grid Projects to Evacuate 21.5 GW Gujarat Renewable Energy

REC subsidiary RECPDCL has floated two large interstate transmission tenders to evacuate power from 21.5 GW of renewable energy projects in Gujarat

Published on 08-May-2026 09:09

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app